AbbVie (TSX:ABBV) Cyclically Adjusted Revenue per Share: C$4.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:ABBV AbbVie Inc TSX:ABBV
83 GF Score
Price C$36.94
GF Value C$30.54
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted Revenue per Share?

AbbVie TSX:ABBV +1.43% 83 Cyclically Adjusted Revenue per Share is C$4.52 as of Jun. 2026. GuruFocus rates TSX:ABBV with a GF Score™ of 83/100 and a GF Value™ of C$30.54 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AbbVie's adjusted revenue per share for the three months ended in Jun. 2026 was C$1.425. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$4.52 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AbbVie's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AbbVie was 14.30% per year. The lowest was 8.90% per year. And the median was 11.20% per year.

As of today (2026-08-22), AbbVie's current stock price is C$36.94. AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was C$4.52. AbbVie's Cyclically Adjusted PS Ratio of today is 8.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.17. The lowest was 4.91. And the median was 6.36.


AbbVie  (TSX:ABBV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AbbVie's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.94/4.52
=8.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.17. The lowest was 4.91. And the median was 6.36.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AbbVie Cyclically Adjusted Revenue per Share Related Terms


AbbVie Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted Revenue per Share Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.53 3.82 4.11 4.36

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.27 4.31 4.36 4.45 4.52

TSX:ABBV vs MRK, JNJ, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.


TSX:ABBV
83GF Score
AbbVie Inc TSX:ABBV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.425/333.9520*333.9520
=1.425

Current CPI (Jun. 2026) = 333.9520.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.544 241.428 0.752
201612 0.590 241.432 0.816
201703 0.578 243.801 0.792
201706 0.611 244.955 0.833
201709 0.567 246.819 0.767
201712 0.651 246.524 0.882
201803 0.680 249.554 0.910
201806 0.731 251.989 0.969
201809 0.750 252.439 0.992
201812 0.787 251.233 1.046
201903 0.747 254.202 0.981
201906 0.782 256.143 1.020
201909 0.801 256.759 1.042
201912 0.816 256.974 1.060
202003 0.858 258.115 1.110
202006 0.908 257.797 1.176
202009 1.018 260.280 1.306
202012 1.055 260.474 1.353
202103 0.975 264.877 1.229
202106 1.016 271.696 1.249
202109 1.082 274.310 1.317
202112 1.133 278.802 1.357
202203 1.020 287.504 1.185
202206 1.113 296.311 1.254
202209 1.177 296.808 1.324
202212 1.221 296.797 1.374
202303 0.997 301.836 1.103
202306 1.101 305.109 1.205
202309 1.126 307.789 1.222
202312 1.143 306.746 1.244
202403 0.995 312.332 1.064
202406 1.184 314.175 1.259
202409 1.170 315.301 1.239
202412 1.282 315.605 1.357
202503 1.144 319.799 1.195
202506 1.260 322.561 1.304
202509 1.303 324.800 1.340
202512 1.366 324.054 1.408
202603 1.228 330.213 1.242
202606 1.425 333.952 1.425

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of C$4.52 mean?
AbbVie (TSX:ABBV) has a Cyclically Adjusted Revenue per Share of C$4.52 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AbbVie and its competitors.
Is AbbVie's Cyclically Adjusted Revenue per Share too high?
AbbVie's current Cyclically Adjusted Revenue per Share is C$4.52. Overall, AbbVie has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Cyclically Adjusted Revenue per Share compare to MRK and JNJ?
AbbVie's Cyclically Adjusted Revenue per Share of C$4.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AbbVie and its competitors. AbbVie's current Cyclically Adjusted Revenue per Share is C$4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (TSX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is C$30.54, compared to a current price of C$36.94 — trading 21% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is C$4.52. AbbVie's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AbbVie (TSX:ABBV), the current Cyclically Adjusted Revenue per Share is C$4.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (TSX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of C$36.94 is trading 21% above its estimated GF Value™ of C$30.54. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for TSX:ABBV:

  • Cyclically Adjusted Revenue per Share: C$4.52
  • GF Value™: C$30.54 vs. price of C$36.94 (21% above fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the TSX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
83GF Score

Get the complete analysis for TSX:ABBV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$36.94
Price
C$30.54
GF Value